680,000 patients in the USA alone suffer from End Stage Renal Disease and millions more around the world.
ESRD treatment costs Medicare $34 billion per year.
Nearly 100,000 Americans are on the wait list for a kidney transplant. Average wait time is 3-7 years.
US Kidney Research Corporation (formerly Curion Research Corporation), is a Delaware
C-Corp founded in June, 2015. For nearly 4 years, US Kidney Research Corporation has been involved in R&D of the world’s first waterless renal replacement technology. Unlike standard dialysis, our new technology does not require water, dialysate concentrate solutions, or a dialyzer. Initially, our technology will be used to develop a wearable artificial kidney.
Ultimately, the same technology can be used in a standalone waterless renal therapy machine and implantable devices.
US Kidney Research Corporation has filed USPTO and PCT patent applications on the technologies utilized covering eventual use in the aforementioned devices.
This revolutionary technology for purifying the blood of patients with end stage kidney disease has the potential to completely replace current dialysis procedures in an industry that has not changed its methodology in decades. In collaboration with advisers and research scientists from two major universities, US Kidney Research Corporation has made significant progress in achieving its goals. It is our intention to bring this new technology to clinical practice and help all those suffering from end stage renal disease.
US Kidney Research Corporation has developed a unique technology that represents a fundamental paradigm shift in renal replacement therapy and has the potential to significantly improve the care of kidney patients worldwide.